In IDH-mut gliomas the survival effect of intact CDKN2A/B resembles that of the survival benefit from post-radiation chemotherapy in low grade IDH-mut gliomas (HR = 0.38) in the RTOG9802 trial [3]. This evidence concerns the gene CDKN2A and central nervous system cancer.